Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Inosine Pranobex
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DCGI Approved Themis Medicare’s Viralex Effective Against Covid-19, Viral Respiratory Infections
Details : VIRALEX (inosine pranobex) is an immunomodulatory agent with antiviral activity across a broad spectrum. It boosts the body’s defenses against viral infections by enhancing both innate and adaptive immunity.
Product Name : Viralex
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Inosine Pranobex
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inosine Pranobex
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Approval for VIRALEX® (Inosine pranobex) is based on the results of Phase 3 trial demonstrated, 80.17% of patients treated with VIRALEX® showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group.
Product Name : Viralex
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Inosine Pranobex
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
